RING Domain–deficient BRCA1 Promotes PARP Inhibitor and Platinum Resistance

Journal of Clinical Investigation- United States

doi 10.1172/jci87033

Full Text

Abstract

Available in

Categories

Medicine

Date

Authors

Publisher

American Society for Clinical Investigation

Related search

Reversion and Non-Reversion Mechanisms of Resistance to PARP Inhibitor or Platinum Chemotherapy in BRCA1/2-mutant Metastatic Breast Cancer

2019English

A Unique Subset of Epithelial Ovarian Cancers With Platinum Sensitivity and PARP Inhibitor Resistance

Cancer Research
Cancer ResearchOncology
2015English

CTLA-4 Blockade Synergizes Therapeutically With PARP Inhibition in BRCA1-Deficient Ovarian Cancer

Cancer immunology research
Cancer ResearchImmunology
2015English

Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2 -Mutated Carcinomas

Cell Reports
BiochemistryGeneticsMolecular Biology
2018English

F-Box Protein-Mediated Resistance to PARP Inhibitor Therapy

Molecular Cell
Cell BiologyMolecular Biology
2019English

The PARP Inhibitor AZD2281 (Olaparib) Induces Autophagy/Mitophagy in BRCA1 and BRCA2 Mutant Breast Cancer Cells

International Journal of Oncology
Cancer ResearchOncology
2015English

PARP Inhibitor Veliparib and HDAC Inhibitor SAHA Synergistically Co-Target the UHRF1/BRCA1 DNA Damage Repair Complex in Prostate Cancer Cells

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2018English

EZH2 Promotes Cisplatin Resistance by Reducing Cellular Platinum Accumulation

Cancer Science
Cancer ResearchMedicineOncology
2018English

The ASCIZ-DYNLL1 Axis Promotes 53bp1-Dependent Non-Homologous End Joining and PARP Inhibitor Sensitivity

Nature Communications
AstronomyGeneticsMolecular BiologyBiochemistryChemistryPhysics
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy